2-fold-rise in anti-S binding IgG concentration;4-fold-rise in anti-S binding IgG concentration;Hemagglutination inhibition (HAI) individual titer;Individual anti-S binding IgG concentration;Individual anti-S binding IgG concentration ratio D22/D01;Individual HAI titers ratio D22/D01;Number of participants with immediate adverse events (AEs);Number of participants with influenza vaccine antibody titer ≥ 10;Number of participants with influenza vaccine antibody titer ≥ 40;Number of participants with medically attended adverse events (MAAE)s;Number of participants with serious adverse events (SAEs) and Adverse Events of Special Interest (AESIs);Number of participants with seroconversion;Number of participants with solicited injection site reactions or systemic reactions;Number of participants with unsolicited AEs

2-fold-rise in anti-S binding IgG concentration;4-fold-rise in anti-S binding IgG concentration;Hemagglutination inhibition (HAI) individual titer;Individual anti-S binding IgG concentration;Individual anti-S binding IgG concentration ratio D22/D01;Individual HAI titers ratio D22/D01;Number of participants with immediate adverse events (AEs);Number of participants with influenza vaccine antibody titer ≥ 10;Number of participants with influenza vaccine antibody titer ≥ 40;Number of participants with medically attended adverse events (MAAE)s;Number of participants with serious adverse events (SAEs) and Adverse Events of Special Interest (AESIs);Number of participants with seroconversion;Number of participants with solicited injection site reactions or systemic reactions;Number of participants with unsolicited AEs